

**X4 PHARMACEUTICALS, INC.**  
61 North Beacon Street, 4<sup>th</sup> Floor  
Boston, MA 02134

December 30, 2021

VIA EDGAR

United States Securities and Exchange Commission  
Division of Corporation Finance  
100 F Street, N.E.  
Washington, D.C. 20549  
Attn: Jordan Nimitz

**RE: X4 Pharmaceuticals, Inc.**  
**Registration Statement on Form S-3**  
**File No. 333-261871**

**Acceleration Request**

**Requested Date: January 3, 2022**  
**Requested Time: 4:00 p.m. Eastern Time**

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Exchange Act of 1933, as amended, the undersigned registrant hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-261871) (the "**Registration Statement**") to become effective at 4:00 p.m. Eastern Time on Monday, January 3, 2022, or as soon thereafter as is practicable.

Once the Registration Statement has been declared effective, please orally confirm that event with Daniel I. Goldberg of Cooley LLP, counsel to the registrant, at (212) 479-6722.

*[Signature page follows]*

---

Sincerely,

**X4 PHARMACEUTICALS, INC.**

By: /s/ Adam S. Mostafa

Adam S. Mostafa

Chief Financial Officer

cc: Paula Ragan, Ph.D., Chief Executive Officer, X4 Pharmaceuticals, Inc.  
Derek Meisner, Chief Legal Officer, X4 Pharmaceuticals, Inc.  
Daniel I. Goldberg, Cooley LLP  
Courtney T. Thorne, Cooley LLP